Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 30;22(1):34.
doi: 10.1186/s12962-024-00533-4.

Impact of including productivity costs in economic analyses of vaccines for C. difficile infections and infant respiratory syncytial virus, in a UK setting

Margherita Neri  1 , Janne C Mewes  2 , Fernando Albuquerque de Almeida  3 , Sophia Stoychev  3 , Nadia Minarovic  3 , Apostolos Charos  3 , Kimberly M Shea #  3 , Lotte M G Steuten #  4
Affiliations

Impact of including productivity costs in economic analyses of vaccines for C. difficile infections and infant respiratory syncytial virus, in a UK setting

Margherita Neri et al. Cost Eff Resour Alloc. .

Abstract

Objectives: It has been estimated that vaccines can accrue a relatively large part of their value from patient and carer productivity. Yet, productivity value is not commonly or consistently considered in health economic evaluations of vaccines in several high-income countries. To contribute to a better understanding of the potential impact of including productivity value on the expected cost-effectiveness of vaccination, we illustrate the extent to which the incremental costs would change with and without productivity value incorporated.

Methods: For two vaccines currently under development, one against Cloistridioides difficile (C. difficile) infection and one against respiratory syncytial disease (RSV), we estimated their incremental costs with and without productivity value included and compared the results.

Results: In this analysis, reflecting a UK context, a C. difficile vaccination programme would prevent £12.3 in productivity costs for every person vaccinated. An RSV vaccination programme would prevent £49 in productivity costs for every vaccinated person.

Conclusions: Considering productivity costs in future cost-effectiveness analyses of vaccines for C. difficile and RSV will contribute to better-informed reimbursement decisions from a societal perspective.

Keywords: C. difficile infection; Economic evaluation; Productivity losses; Respiratory syncytial virus; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Neri, Steuten report grants from Pfizer to OHE Consulting Ltd, during the conduct of the study, and grants from various pharmaceutical companies to OHE Consulting Ltd outside the submitted work. Albuquerque de Almeida, Stoychev, Minarovic, Charos, Shea are employees of Pfizer and may hold Pfizer stocks or stock options.

Figures

Fig. 1
Fig. 1
Difference in costs between standard of care and C. difficile vaccination strategy*, without and with productivity costs. * All results are net of the vaccine cost
Fig. 2
Fig. 2
Difference in costs between standard of care and RSV vaccination strategy*, without and with productivity costs. * All results are net of the vaccine cost, which cancels out in the comparison
See this image and copyright information in PMC

References

    1. Debrabant K. Productivity losses impact cost effectiveness of COVID-19 vaccine. PharmacoEconomics Outcomes News. 2021;890:21–30. doi: 10.1007/s40274-021-08144-y. - DOI - PMC - PubMed
    1. Bärnighausen T, Bloom DE, Cafiero ET, O’Brien JC. Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus. Clin Microbiol Infection: Official Publication Eur Soc Clin Microbiol Infect Dis. 2012;18(Suppl 5):70–6. doi: 10.1111/j.1469-0691.2012.03977.x. - DOI - PubMed
    1. Bärnighausen T, Bloom DE, Canning D, Friedman A, Levine OS, O’Brien J, et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. Vaccine. 2011;29(13):2371–80. doi: 10.1016/j.vaccine.2010.11.090. - DOI - PubMed
    1. Jit M, Hutubessy R, Png ME, Sundaram N, Audimulam J, Salim S, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13:209. doi: 10.1186/s12916-015-0446-9. - DOI - PMC - PubMed
    1. Sevilla JP, Stawasz A, Burnes D, Agarwal A, Hacibedel B, Helvacioglu K, et al. Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey. Hum Vaccines Immunotherapeutics. 2020;16(8):1923–36. doi: 10.1080/21645515.2019.1708668. - DOI - PMC - PubMed

LinkOut - more resources